Verik Is Committed To Creating The Best
Curative Treatment Options For Advanced Cancer
Curative by Design™
Our mission is to apply the best know-how, science, technology and innovation to achieve the full curative potential of Adoptive (T) Cell Therapy (ACT).
We believe that achieving this goal starts with a High Curative Potential™ (HCP) target; however, successful delivery takes a combination of the right modality, focused application, use of technology, perspective, and innovation.
Biology Determines the Best Targets more
The heart of our Biology-First™ strategy is the selection of targets at a nexus of tumor’s regenerative capacity because a cell’s ability to perpetuate the cancer is arguably the most-deadly property.
ACT Delivers a Reliable Potency more
Verik’s approach to cancer immunotherapy takes full advantage of ACT as a curative, equal opportunity modality by addressing current limitations to achieving broad application with robust results. We believe that engineered T cell therapy is the most direct path to a cure.
Solid Tumors Focus ACT on the Major Need more
Our focus is on optimizing the application of ACT in advanced carcinomas (80% of patients) using our expertise in epithelial biology.
T Cell Receptors (TCRs) Create Options more
Our SeleCTR™ platform has been designed to enable discovery and efficient development of TCR-based therapies as the most productive path to HCP ACT.
HCP Increases Commercial Feasibility more
By linking the target to biology pivotal to perpetuation:
- Expression is retained as the cancer evolves and metastasizes, which increases the likelihood of achieving a durable response.
- The targeted protein is more likely a shared protein, translating to higher commercial feasibility.
Specificity Supports Broad Adoption more
The potential for on-target and off-target toxicity is addressed upfront in Verik's SeleCTR platform. Targets are stringently cancer-specific and their High Probability epitopes are subject to a final algorithm screen for neoantigen specificity before a peptide sequence is cleared for use in TCR selection.